

DAFTAR PUSTAKA

1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. *N Engl J Med*. 2006;355:1345–56.
2. De Waele L, Lagae L, Mekahli D. Tuberous sclerosis complex: the past and the future. *Pediatr Nephrol*. 2015;30:1771–80.
3. Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 international tuberous sclerosis complex consensus conference. *Pediatr Neurol*. 2013;49:243–54.
4. Hinton RB, Prakash A, Romp RL, Krueger DA, Knilans TK. Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the international tuberous sclerosis consensus group. *J Am Heart Assoc*. 2014;3:1–12.
5. Curatolo P, Moavero R, De Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. 2015;
6. Roth J, Roach ES, Bartels U, Jóźwiak S, Koenig MK, Weiner HL, et al. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. *Pediatr Neurol*. 2013;49:439–44.
7. Teng JMC, Cowen EW, Wataya-Kaneda M, Gosnell ES, Witman PM, Hebert AA, et al. Dermatologic and Dental Aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements. *JAMA Dermatology*. 2014;150:1095.
8. Petrus J. de Vries, MBChB, MRCPsych, PhDa,*, Vicky H. Whittemore, PhDb, Loren Leclezio, MSc(Neurosci)a, Anna W. Byars, PhDc, David Dunn, MDd, Kevin C. Ess, MD, PhD, Dena Hookf, Bryan H. King, MD, MBag, Mustafa Sahin, MD, PhDh, and Anna Jansen Md. Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) and the TAND Checklist. *Pediatr Neurol*. 2015;52:25–35.
9. Krueger DA, Northrup H. Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference on behalf of the International Tuberous Sclerosis Complex Consensus Group. *Pediatr Neurol*. 2013;49:255–65.
10. Ng KH, Ng SM, Parker A. Annual review of children with tuberous sclerosis. *Arch Dis Child Educ Pract Ed*. 2015;100:114–21.
11. Zöllner JP, Franz DN, Hertzberg C, Nababout R, Rosenow F, Sauter M, et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). *Orphanet J Rare Dis*. 2020;15.
12. Rentz AM, Skalicky AM, Liu Z, Wheless JW, Dunn DW, Frost MD, et al. Tuberous sclerosis complex: a survey of health care resource use and health burden. *Pediatr Neurol*. 2015;52:435–41.
13. Saltık S, Karatoprak EY, Taşel B. Characteristics and the clinical prognosis of epilepsy in patients with a diagnosis of tuberous sclerosis complex.

- 2012;
14. Park SM, Lee YJ, Son YJ, Kim YO, Woo YJ. Clinical Progress of Epilepsy in Children with Tuberous Sclerosis: Prognostic Factors for Seizure Outcome. *Chonnam Med J Chonnam Med J*. 2011;47:150–4.
 15. Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. *Pediatr Neurol*. 2021;123:50–66.
 16. Ebrahimi-Fakhari D, Mann LL, Poryo M, Graf N, Von Kries R, Heinrich B, et al. Correction to: Incidence of tuberous sclerosis and age at first diagnosis: New data and emerging trends from a national, prospective surveillance study (Orphanet Journal of Rare Diseases. (2018) 13 (117) DOI: 10.1186/s13023-018-0870-y). *Orphanet J Rare Dis*. 2019;14:1–8.
 17. Józwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. *J Child Neurol*. 2000;15:652–9.
 18. Isaacs H. Perinatal (fetal and neonatal) tuberous sclerosis: A review. *Am J Perinatol*. 2009;26:755–60.
 19. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17:405–24.
 20. Hoogeveen-Westerveld M, Ekong R, Povey S, Mayer K, Lannoy N, Elmslie F, et al. Functional Assessment of TSC2 Variants Identified in Individuals with Tuberous Sclerosis Complex. *Hum Mutat*. 2013;34:167–75.
 21. Nellist M, van den Heuvel D, Schluep D, Exalto C, Goedbloed M, Maat-Kievit A, et al. Missense mutations to the TSC1 gene cause tuberous sclerosis complex. *Eur J Hum Genet*. 2009;17:319–28.
 22. Cardis MA, Deklotz CMC. Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role. *Arch Dis Child*. 2017;102:858–63.
 23. Ebrahimi-Fakhari D, Meyer S, Vogt T, Pföhler C, Müller CSL. Dermatological manifestations of tuberous sclerosis complex (TSC). *JDDG - J Ger Soc Dermatology*. 2017;15:695–700.
 24. Curatolo P, Verdecchia M, Bombardieri R. Tuberous sclerosis complex: A review of neurological aspects. Vol. 6, *European Journal of Paediatric Neurology*. 2002. p. 15–23.
 25. Cusmai R, Moavero R, Bombardieri R, Vigevano F, Curatolo P. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. *Epilepsy Behav* [Internet]. 2011;22:735–9. Available from: <http://dx.doi.org/10.1016/j.yebeh.2011.08.037>
 26. Mous SE, Overwater IE, Vidal Gato R, Duvekot J, ten Hoopen LW, Lequin MH, et al. Cortical dysplasia and autistic trait severity in children with Tuberous Sclerosis Complex: a clinical epidemiological study. *Eur Child Adolesc Psychiatry*. 2018;27:753–65.

27. Yates JRW, MacLean C, Higgins JNP, Humphrey A, Le Maréchal K, Clifford M, et al. The tuberous sclerosis 2000 study: Presentation initial assessments and implications for diagnosis and management. *Arch Dis Child*. 2011;96:1020–5.
28. Russo C, Nastro A, Cicala D, De Liso M, Covelli EM, Cinalli G. Neuroimaging in tuberous sclerosis complex. *Child's Nerv Syst*. 2020;36:2497–509.
29. Saxena A, Sampson JR. Epilepsy in tuberous sclerosis: Phenotypes, mechanisms, and treatments. *Semin Neurol*. 2015;35:269–76.
30. Curatolo P, D'Argenzio L, Cerminara C, Bombardieri R. Management of epilepsy in tuberous sclerosis complex. *Expert Rev Neurother*. 2008;8:457–67.
31. Yamamoto N, Watanabe K, Negoro T, Matsumoto A, Miyazaki S, Kumagai T, et al. Long-term prognosis of tuberous sclerosis with epilepsy in children. *Brain Dev*. 1987;9:292–5.
32. Schuele SU, Lüders HO. Intractable epilepsy: management and therapeutic alternatives. *Lancet Neurol*. 2008;7:514–24.
33. Vignoli A, Briola F La, Turner K, Scornavacca G, Chiesa V, Zambrelli E, et al. Epilepsy in TSC: Certain etiology does not mean certain prognosis. *Epilepsia*. 2013;54:2134–42.
34. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. *Epilepsia*. 2010;51:1236–41.
35. Moavero R, Bombardieri R, Marciano S, Cerminara C. Epilepsy in Tuberous Sclerosis Complex. *J Pediatr Epilepsy*. 2016;5:64–9.
36. Curatolo P, Jóźwiak S, Nabbout R, TSC Consensus Meeting for SEGA and Epilepsy Management. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. *Eur J Paediatr Neurol*. 2012;16:582–6.
37. Wirrell EC, Nabbout R, Scheffer IE, Alsaadi T, Bogacz A, French JA, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions. *Epilepsia*. 2022;63:1333–48.
38. Kemenkes RI. Pedoman Tatalaksana Klinis Infeksi Saluran Pernapasan Akut Berat Suspek Middle East Respiratory Syndrome-Corona Virus (Mers-Cov). 2013;1–18.
39. Karalis V, Bateup HS. Current Approaches and Future Directions for the Treatment of mTORopathies. *Dev Neurosci*. 2021;43:143–58.
40. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. *JAMA*. 1998;279:1100–7.
41. Kingswood JC, de Vries PJ. Tuberous sclerosis complex. *Paediatr Child Heal (United Kingdom)*. 2015;25:467–73.
42. Staley BA, Vail EA, Thiele EA. Tuberous Sclerosis Complex: Diagnostic Challenges, Presenting Symptoms, and Commonly Missed Signs.

- Pediatrics*. 2011;127:e117–25.
43. Hinton RB, Prakash A, Romp RL, Krueger DA, Knilans TK. Cardiovascular Manifestations of Tuberous Sclerosis Complex and Summary of the Revised Diagnostic Criteria and Surveillance and Management Recommendations From the International Tuberous Sclerosis Consensus Group.
 44. Mammadova D, Vecko J, Hofmann M, Schüssler SC, Deiters L, Canda A, et al. A single-center observational study on long-term neurodevelopmental outcomes in children with tuberous sclerosis complex. *Orphanet J Rare Dis* [Internet]. 2023;18:1–13. Available from: <https://doi.org/10.1186/s13023-023-02959-0>
 45. Appleton RE, Cross H. Drug treatment of paediatric epilepsy. *Pediatr Epilepsy Diagnosis Ther*. 2012;586.
 46. Jovanovic M, Jovic-Jakubi B, Stevanovic D. Adverse effects of antiepileptic drugs and quality of life in pediatric epilepsy. *Neurol India*. 2015;63:353–9.
 47. McCracken J. The New England Journal of Medicine Risperidone In Children With Autism And Serious Behavioral Problems ABSTRACT Background Atypical antipsychotic agents, which. *N Engl J Med* [Internet]. 2002;347:314–21. Available from: www.nejm.org
 48. D Isaacson, J L Mueller JCN and SS, Article R. NIH Public Access. *Bone*. 2006;23:1–7.
 49. Specchio N, Nabbout R, Aronica E, Auvin S, Benvenuto A, de Palma L, et al. Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy. *Eur J Paediatr Neurol* [Internet]. 2023;47:25–34. Available from: <https://doi.org/10.1016/j.ejpn.2023.08.005>
 50. Overwater IE, Bindels-De Heus K, Rietman AB, Ten Hoopen LW, Vergouwe Y, Moll HA, et al. Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. *Epilepsia*. 2015;56:1239–45.
 51. Rahman MM, Fatema K. Epilepsy in Children with Tuberous Sclerosis Complex: A Prospective Observational Study in Bangladesh. *J Epilepsy Res*. 2020;10:18–23.
 52. Hulshof HM, Heijstek JK, Otte WM, Bruining H, Braun KPJ, Jansen FE. Anti-seizure medication is a minor causative factor in behavioral problems of children with tuberous sclerosis complex. *Epilepsy Behav*. 2025;168:110427.
 53. Kossoff EH, Thiele EA, Pfeifer HH, McGrogan JR, Freeman JM. Tuberous sclerosis complex and the ketogenic diet. *Epilepsia*. 2005;46:1684–6.
 54. Park S, Lee EJ, Eom S, Kang H-C, Lee JS, Kim HD. Ketogenic Diet for the Management of Epilepsy Associated with Tuberous Sclerosis Complex in Children. *J Epilepsy Res*. 2017;7:45–9.
 55. Tye C, Mcewen FS, Liang H, Underwood L, Woodhouse E, Barker ED, et al. Long-term cognitive outcomes in tuberous sclerosis complex. *Dev Med Child Neurol*. 2020;62:322–9.
 56. Bolton PF, Clifford M, Tye C, Maclean C, Humphrey A, le Maréchal K, et

- al. Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study. *Psychol Med* [Internet]. 2015/04/01. 2015;45:2321–31. Available from: <https://www.cambridge.org/core/product/A1C5BF83459F9278016FCE7484CA4927>
57. Tsai JD, Ho MC, Shen CY, Weng JC. Assessment of disrupted brain functional connectome in tuberous sclerosis complex using resting-state fMRI. *Med (United States)*. 2022;101:1–7.
58. Skalicky AM, Rentz AM, Liu Z, Said Q, Nakagawa JA, Frost MD, et al. Economic burden, work, and school productivity in individuals with tuberous sclerosis and their families. *J Med Econ* [Internet]. 2018;21:953–9. Available from: <https://doi.org/10.1080/13696998.2018.1487447>
59. Toldo I, Brasson V, Miscioscia M, Pelizza MF, Manara R, Sartori S, et al. Tuberous sclerosis-associated neuropsychiatric disorders: a paediatric cohort study. *Dev Med Child Neurol*. 2019;61:168–73.
60. Aden M, Fawzi MO, Prosser D, Ather M, Raja M, Ederies MA, et al. Central nervous system manifestations of tuberous sclerosis complex: A single centre experience in Qatar. *Saudi Med J*. 2024;45:1245–52.
61. Lu DS, Karas PJ, Krueger DA, Weiner HL. Central nervous system manifestations of tuberous sclerosis complex. *Am J Med Genet C Semin Med Genet*. 2018;178:291–8.
62. Marcinkowska AB, Jóźwiak S, Tarasewicz A, Dębska-Ślizień A, Szurowska E. Tuberous Sclerosis Complex Patients' Needs and Difficulties-Results of TAND Questionnaire Analysis in Polish Adult Population. *J Clin Med*. 2022;11.
63. Panwar A, Malik S, Kamarthi N, Gupta S, Goel S, Sharma A, et al. Oral manifestations of tuberous sclerosis complex: A systematic review. *Pediatr Dent J* [Internet]. 2024;34:164–81. Available from: <https://www.sciencedirect.com/science/article/pii/S0917239424000247>
64. Öhnell HM, Kjellström U, Eklund E, Pearsson K, Bekassy Z, Gränse L. Ophthalmic manifestations in children with tuberous sclerosis complex. *Acta Ophthalmol*. 2024;102:421–7.
65. Jóźwiak S, Sadowski K, Borkowska J, Domańska-Pakieła D, Chmielewski D, Jurkiewicz E, et al. Liver Angiomyolipomas in Tuberous Sclerosis Complex—Their Incidence and Course. *Pediatr Neurol*. 2018;78:20–6.
66. Warncke JC, Brodie KE, Grantham EC, Catarinichia SP, Tong S, Kondo KL, et al. Pediatric Renal Angiomyolipomas in Tuberous Sclerosis Complex. *J Urol*. 2017;197:500–6.
67. de Vries PJ, Wilde L, de Vries MC, Moavero R, Pearson DA, Curatolo P. A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). *Am J Med Genet C Semin Med Genet*. 2018;178:309–20.
68. Amin S, Mallick AA, Lux A, O'Callaghan F. Quality of life in patients with Tuberous Sclerosis Complex (TSC). *Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc*. 2019;23:801–7.